400 868 3000

Jiahui App

Wechat Contact

Whats App

嘉会国际肿瘤中心 JIAHUI INTERNATIONAL CANCER CENTER

    NEWS AND ARTICLES

    World’s First International Solid Tumor CAR-T Patient Completes Treatment at Jiahui International Cancer Center

    World’s First International Solid Tumor CAR-T ...

    The world’s first international patient to receive Satri-cel (CT041), the newly approved CA...

    World’s First Approved Bispecific ADC Izalontamab Brengitecan for Injection Now Available at Jiahui International Cancer Center

    World’s First Approved Bispecific ADC Izalonta...

    Izalontamab Brengitecan for Injection, a first-in-class novel EGFR×HER3 bispecific antibody...

    World’s First International Patient Starts Newly Approved Solid Tumor CAR-T

    World’s First International Patient Starts New...

    The world's first international patient to receive Satri-cel, the newly approved CAR-T ther...

    A Historic Milestone in Oncology: World's First Solid Tumor CAR-T Therapy Approved in China

    A Historic Milestone in Oncology: World's Firs...

    Jiahui International Cancer Center welcomes the approval of Satri-cel (CT041, Kaileimei®), ...

    U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China

    U.S. Patient with Advanced Lung Cancer Stabili...

    Jiahui International Cancer Center (JICC) provided treatment to an American patient with ad...

    From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma

    From Pakistan to Shanghai: A CAR-T Journey Fig...

    Searching Beyond Standard TreatmentAt 36 years old, Muhammad had already undergone years of...

    More

    Contact Us

    Jiahui Partners

    Copyright © 2017 by Jiahui,Inc. All rights reserved 沪ICP备 15019023号 | 沪公网安备 31010402004841 号